Press Releases

Press Releases

Date Title and Summary  
Toggle Summary AVEO Oncology to Present TIVO-3 Data at the 2019 ASCO Genitourinary Cancers Symposium
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 2, 2019-- AVEO Oncology (NASDAQ: AVEO ) today announced that data from the Phase 3 TIVO -3 study of tivozanib (FOTIVDA ® ) versus sorafenib in refractory advanced or metastatic renal cell carcinoma (RCC) will be presented during an oral session at the 2019
Printer Friendly Version
Toggle Summary AVEO Oncology to Present at the 37th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 2, 2019-- AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey , president and chief executive officer, will present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 9, 2019 at 4:00 p.m. Pacific Time .
Printer Friendly Version
Toggle Summary AVEO Oncology Announces NDA Timing Update
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 31, 2019-- AVEO Oncology (NASDAQ: AVEO ) today announced that it has accepted the recommendation of the U.S. Food and Drug Administration ( FDA ) not to submit a New Drug Application (NDA) for tivozanib (FOTIVDA®) with the preliminary overall survival (OS)
Printer Friendly Version
Toggle Summary AVEO Oncology Announces Oral Presentation of TIVO-3 Trial Topline Results at the 2019 ASCO Genitourinary Cancers Symposium
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 16, 2019-- AVEO Oncology (NASDAQ:AVEO) today announced the presentation of data from the Phase 3 TIVO -3 study of tivozanib (FOTIVDA ® ) versus sorafenib in refractory advanced or metastatic renal cell carcinoma (RCC).
Printer Friendly Version
Toggle Summary AVEO Oncology to Present at the 8th Annual SVB Leerink Global Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 20, 2019-- AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey , president and chief executive officer, will present at the 8th Annual SVB Leerink Global Healthcare Conference in New York on Wednesday, February 27, 2019 at 2:30 p.m.
Printer Friendly Version
Toggle Summary AVEO Oncology Announces Appointment of Gregory T. Mayes to its Board of Directors
- John H. Johnson to Step Down from Board; Will Remain an Advisor to the Company - CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 26, 2019-- AVEO Oncology (NASDAQ: AVEO ) today announced the appointment of Gregory T. Mayes to its Board of Directors. Mr. Mayes brings to the AVEO Board over 20 years of
Printer Friendly Version
Toggle Summary AVEO Reports Full Year 2018 Financial Results and Provides Business Update
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 14, 2019-- AVEO Oncology (NASDAQ: AVEO ) today reported financial results for the full year ended December 31, 2018 and provided a business update. “The results of TIVO -3, presented in February at the 2019 ASCO GU Symposium, underscore a unique activity and
Printer Friendly Version
Toggle Summary AVEO and Biodesix Announce Positive Results from Phase Ib Ficlatuzumab-Cytarabine Trial in Patients with Relapsed and Refractory AML
- Data presented during poster session at the AACR 2019 Annual Meeting - CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 1, 2019-- AVEO Oncology (NASDAQ:AVEO) and Biodesix, Inc. today announced results from an investigator-sponsored Phase Ib expansion cohort of ficlatuzumab, AVEO’s potent hepatocyte
Printer Friendly Version
Toggle Summary AVEO Oncology to Present at the H.C. Wainwright Global Life Sciences Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 2, 2019-- AVEO Oncology (NASDAQ: AVEO ) today announced that Michael Bailey , president and chief executive officer, will present at the H.C. Wainwright Global Life Sciences Conference in London on Tuesday, April 9, 2019 at 2:10 p.m. BST .
Printer Friendly Version
Toggle Summary AVEO Pharmaceuticals, Inc. Announces Proposed Public Offering
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 3, 2019-- AVEO Pharmaceuticals, Inc. (Nasdaq: AVEO ) (“AVEO” or the “Company”), a biopharmaceutical company seeking to advance targeted medicines for oncology and other unmet medical needs, today announced it has commenced an underwritten public offering of
Printer Friendly Version
Toggle Summary AVEO Pharmaceuticals, Inc. Announces Pricing of $25 Million Underwritten Public Offering
CAMBRIDGE, Mass.--( BUSINESS WIRE )--AVEO Pharmaceuticals, Inc. (Nasdaq: AVEO) (“AVEO” or the “Company”), a biopharmaceutical company seeking to advance targeted medicines for oncology and other unmet medical needs, today announced the pricing of its previously announced underwritten public
Printer Friendly Version
Toggle Summary AVEO Oncology Announces $2M Milestone Payment From EUSA Pharma Related To Commercialization of FOTIVDA® in Spain
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 23, 2019-- AVEO Oncology (NASDAQ:AVEO) today announced the triggering of a $2 million milestone payment to AVEO from EUSA Pharma. The milestone payment relates to the reimbursement approval and commercial launch in Spain of FOTIVDA ® (tivozanib) as a first
Printer Friendly Version
Toggle Summary AVEO Oncology to Participate in the 5th Annual SunTrust Robinson Humphrey Life Sciences Summit
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 1, 2019-- AVEO Oncology (NASDAQ:AVEO) today announced that members of the management team will participate in the 5th Annual SunTrust Robinson Humphrey Life Sciences Summit on Wednesday, May 8, 2019 . The conference is being held May 7-8 in New York .
Printer Friendly Version
Toggle Summary AVEO Reports First Quarter 2019 Financial Results and Provides Business Update
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 9, 2019-- AVEO Oncology (NASDAQ: AVEO ) today reported financial results for the first quarter ended March 31, 2019 and provided a business update. “With a successful recent equity offering, together with the triggering of a FOTIVDA ® (tivozanib) milestone
Printer Friendly Version
Toggle Summary AVEO Oncology Announces Presentations at the 2019 ASCO Annual Meeting
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 15, 2019-- AVEO Oncology (NASDAQ: AVEO ) today announced two poster presentations at the upcoming American Society of Clinical Oncology ( ASCO ) Annual Meeting being held May 31-June 4, 2019 in Chicago, Illinois .
Printer Friendly Version
Toggle Summary AVEO Oncology to Present at the 2019 BIO International Convention
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 29, 2019-- AVEO Oncology (NASDAQ: AVEO ) today announced that Mike Ferraresso , Senior Vice President, Business Analytics and Commercial Operations, will present at the 2019 BIO International Convention in Philadelphia on Wednesday, June 5, 2019 at 4:30 p.m.
Printer Friendly Version
Toggle Summary Kyowa Kirin Buys Back Tivozanib Non-Oncology Rights from AVEO Oncology
TOKYO & CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 1, 2019-- Kyowa Kirin Co., Ltd. , ( Kyowa Kirin , TYO: 4151) and AVEO Oncology (NASDAQ: AVEO ) announce that they have amended their license agreement to allow Kyowa Kirin to buy back the non-oncology rights of tivozanib in AVEO territories, which
Printer Friendly Version
Toggle Summary AVEO Reports Second Quarter 2019 Financial Results and Provides Business Update
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 8, 2019-- AVEO Oncology (NASDAQ: AVEO ) today reported financial results for the second quarter ended June 30, 2019 and provided a business update. “As we move toward reporting more mature interim overall survival (OS) results from our TIVO -3 study of
Printer Friendly Version
Toggle Summary AVEO Oncology Announces Updated Overall Survival Hazard Ratio of 0.99 in Phase 3 TIVO-3 Trial of Tivozanib in Renal Cell Carcinoma
- 20 Patients Remain Progression Free on Tivozanib Arm vs. 2 on Sorafenib Arm - - Company Plans to Discuss Updated Results with FDA - - AVEO to Host Conference Call Today at 8:00 am Eastern Time - CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 10, 2019-- AVEO Oncology (NASDAQ: AVEO ) today announced
Printer Friendly Version
Toggle Summary AVEO Oncology and EUSA Pharma Announce Presentation of Final PFS Results from Phase 2 Portion of the TiNivo Study in Renal Cell Carcinoma
  – Results Suggest Additive or Synergistic Activity in Both Treatment Naïve and Previously Treated Patients –     -Tivozanib-Nivolumab Combination Generally Well Tolerated -     – Data to be Presented at the ESMO 2019 Annual Congress –     CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep.
Printer Friendly Version
Toggle Summary AVEO Oncology to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference
  CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 26, 2019-- AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey , president and chief executive officer, will present at the 2019 Cantor Fitzgerald Global Healthcare Conference in New York on Friday, October 4, 2019 at 10:05 a.m. Eastern Time .
Printer Friendly Version
Toggle Summary AVEO Oncology Announces Initiation of Enrollment in Phase 1b/2 Study of FOTIVDA® (tivozanib) in Combination with IMFINZI® (durvalumab) in Previously Untreated Metastatic Hepatocellular Carcinoma
  CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 30, 2019-- AVEO Oncology (NASDAQ: AVEO ) today announced that it has initiated enrollment in an open-label, multi-center Phase 1b/2 clinical trial evaluating FOTIVDA ® (tivozanib), the Company’s once-daily, potent and selective vascular endothelial growth
Printer Friendly Version
Toggle Summary AVEO Oncology Announces Regulatory Update for Tivozanib in Renal Cell Carcinoma
- NDA Filing Planned for 1Q20 for Relapsed/Refractory RCC – - Company Plans Final OS Analysis in 2Q20 - CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 4, 2019-- AVEO Oncology (NASDAQ: AVEO ) today provided a regulatory update following a meeting with the U.S.
Printer Friendly Version
Toggle Summary AVEO Oncology and Biodesix Announce Initiation of the CyFi-2 Study, a Phase 2 Randomized Study of Ficlatuzumab in Combination with High-Dose Cytarabine vs. High-Dose Cytarabine Alone in Patients with Relapsed and Refractory AML
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 7, 2019-- AVEO Oncology (NASDAQ: AVEO ) and Biodesix, Inc. today announced the initiation of the CyFi-2 study, a randomized Phase 2 clinical study evaluating ficlatuzumab, AVEO’s potent hepatocyte growth factor (HGF) inhibitory antibody product candidate, in
Printer Friendly Version
Toggle Summary AVEO Reports Third Quarter 2019 Financial Results and Provides Business Update
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 12, 2019-- AVEO Oncology (NASDAQ: AVEO ) today reported financial results for the third quarter ended September 30, 2019 and provided a business update. “This quarter we have made meaningful progress toward our goal of bringing effective and better tolerated
Printer Friendly Version
Toggle Summary AVEO Announces Presentation of Updated OS and Subgroup Data from Phase 3 TIVO-3 Trial of Tivozanib in Renal Cell Carcinoma
- Tivozanib Significantly Improves PFS and ORR Compared to Sorafenib and Demonstrates Updated Interim OS HR of 0.99 in Refractory Advanced RCC - - Outcomes Favor Tivozanib in Patients Previously Treated With Checkpoint Inhibitors as Well as Two VEGFR-TKIs - - Data Featured in Oral Presentation at
Printer Friendly Version
Toggle Summary AVEO Oncology Announces Appointment of Scarlett Spring to its Board of Directors
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 19, 2019-- AVEO Oncology (NASDAQ: AVEO ) today announced the appointment of Scarlett Spring to its Board of Directors. Ms. Spring brings to AVEO extensive sales, commercial, and leadership experience in the biopharmaceutical and life sciences industries.
Printer Friendly Version
Toggle Summary AVEO Oncology to Present at the 31st Annual Piper Jaffray Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 26, 2019-- AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey , president and chief executive officer, will present at the 31 st Annual Piper Jaffray Healthcare Conference in New York on Tuesday, December 3, 2019 at 4:30 p.m. Eastern Time .
Printer Friendly Version
Toggle Summary AVEO Oncology Announces Lancet Oncology Publication of Data from Phase 3 TIVO-3 Study of Tivozanib in Renal Cell Carcinoma
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 4, 2019-- AVEO Oncology (NASDAQ: AVEO) today announced that previously reported data from its Phase 3 TIVO -3 study were published in The Lancet Oncology . TIVO -3 is the Company’s Phase 3 randomized, controlled, multi-center, open-label study to compare
Printer Friendly Version